Recent advances in radiation therapy of pancreatic cancer.

Bhanu Prasad Venkatesulu, Cheng En Hsieh, Keith L. Sanders, Sunil Krishnan*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Pancreatic cancer has a dismal prognosis with an overall survival outcome of just 5% at five years. However, paralleling our improved understanding of the biology of pancreatic cancer, treatment paradigms have also continued to evolve with newer advances in surgical techniques, chemotherapeutic agents, radiation therapy (RT) techniques, and immunotherapy paradigms. RT dose, modality, fraction size, and sequencing are being evaluated actively, and the interplay between RT and immune effects has opened up newer avenues of research. In this review, we will emphasize recent advances in RT for pancreatic cancer, focusing on preoperative chemoradiation, RT dose escalation, sparing of the spleen to reduce lymphopenia, and combination of RT with immunotherapy.

Original languageEnglish
Article number1931
StatePublished - 2018

Bibliographical note

Publisher Copyright:
© 2018 Venkatesulu BP et al.


  • Dose escalation
  • Immunotherapy
  • Neoadjuvant therapy
  • Radiotherapy
  • Spleen sparing


Dive into the research topics of 'Recent advances in radiation therapy of pancreatic cancer.'. Together they form a unique fingerprint.

Cite this